-
The Medicines Company Is A Major Cardiovascular Player In The Making
Monday, December 5, 2016 - 12:42pm | 297HC Wainwright has started coverage of The Medicines Company (NASDAQ: MDCO) with a Buy rating and $57 price target on the back of Phase 3-ready inclisiran (PCSK9si). Key Catalyst: Inclisiran Inclisiran is an RNAi therapeutic that inhibits synthesis of PCSK9 directly in the liver for potent and...
-
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
Monday, September 26, 2016 - 11:46am | 550HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. In fact, the brokerage expects the diabetes compounds to be more likely to move the stock...
-
Mirna's Murky Clinical Strategy Leaves HC Wainwright Hesitant
Friday, September 23, 2016 - 10:04am | 401HC Wainwright has downgraded Mirna Therapeutics Inc (NASDAQ: MIRN) to Neutral from Buy as it awaits further steps from the company following the voluntary stop of the MRX34 trial, the company's investigational microRNA therapy for multiple cancers. Mirna stopped its Phase 1 study of MRX34 following...
-
HC Wainwright Bullish On Proteon Therapeutics, Sees 105% Potential Upside
Thursday, September 22, 2016 - 11:15am | 375HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...
-
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target
Thursday, September 22, 2016 - 10:45am | 441HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares with a Buy rating. The firm sees 68 percent potential upside for the pharmaceutical company on upcoming opt-in decisions for its lead drug candidates expected from three partners: Celgene Corporation (NASDAQ:...
-
Tobira Therapeutics Shares Initiated With Buy, $22 Target At HC Wainwright
Monday, April 11, 2016 - 9:10am | 258Tobira Therapeutics Inc (NASDAQ: TBRA) currently has one drug candidate, which has shown promising results in the treatment of non-alcoholic steatohepatitis [NASH] and HIV patients. HC Wainwright’s Ed Arce initiated coverage of the company with a Buy rating and a price target of $22....
-
Digital Ally Falls 5% After Big Earnings Miss
Monday, March 7, 2016 - 4:30pm | 152Early Monday afternoon, Digital Ally, Inc. (NASDAQ: DGLY) reported quarterly results. The release may have been come sooner than planned.Falls Q4's EPS came in at $(0.40) versus an estimated $(0.18). Sales came in at $5.051 million versus the estimated $5.70 million. Following this...
-
Proteostasis Therapeutics Shares Initiated With Buy, $15 Price Target
Monday, March 7, 2016 - 10:35am | 262HC Wainwright’s Andrew S. Fein initiated coverage of Proteostasis Therapeutics Inc (NASDAQ: PTI) with a Buy rating and a price target of $15. The company develops disease-modifying therapeutics for diseases related to protein processing. At a time when combination-driven treatments are...
-
Buy Ligand Shares; HC Wainwright Sets $146 Price Target
Thursday, March 3, 2016 - 10:04am | 243HC Wainwright initiated coverage of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) with a Buy rating and 12 month price target of $146, saying Ligand is a profitable unique company that has royalty rights to over 140 potential medicines that its 85+ partners are funding the development. Analyst...
-
Streetsweeper Goes Negative On Second Sight, Says These Risks Are 'Eye-Opening'
Wednesday, February 24, 2016 - 2:51pm | 382Shares of Second Sight Medical Products Inc (NASDAQ: EYES) surged higher on Monday after the company's medical technology was featured in a preview in an upcoming Vice documentary. However, shares tumbled on Wednesday after the company received some negative press in the form of a...
-
Galectin Therapeutics Could Triple On Fibrosis And Cirrhosis Treatment
Monday, September 21, 2015 - 10:13am | 341Shares of Galectin Therapeutics, Inc. (NASDAQ: GALT) have declined more than 32 percent year-to-date. HC Wainwright’s Yi Chen has initiated coverage of Galectin Therapeutics with a Buy rating and $7 price target. The company is developing a treatment for nonalcoholic steatohepatitis...
-
3 Catalysts To Watch Over The Next Couple Months For This Pharma Co.
Wednesday, September 2, 2015 - 11:18am | 263AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares are down 33 percent year-to-date after having peaked at $9.32 on March 2. HC Wainwright analyst Ed Arce initiated coverage of the company with a Buy rating and a price target of $8.50. Three critical milestones within the next two months...
-
TG Therapeutics: A Buy Worth $22
Wednesday, August 12, 2015 - 7:46am | 224In a report published Wednesday, HC Wainwright analyst Andrew S Fein resumed coverage of TG Therapeutics Inc. (NASDAQ: TGTX) with a Buy rating and a price target of $22. TG Therapeutics' product pipeline offered "internal and external combination options whose efficacy and safety profiles bode well...
-
H.C. Wainwright: Biogen Is Now A Buy Worth $380/Share
Tuesday, August 11, 2015 - 9:06am | 175In a report published Tuesday, HC Wainwright analyst Andrew S. Fein initiated coverage of Biogen Inc (NASDAQ: BIIB) with a Buy rating and a price target of $380. Biogen's Alzheimer's disease product pipeline assets provided an opportunity for combination therapy, an approach that would be required...
-
H.C. Wainwright Destroys Epizyme Price Target, Sees 'No Material Value Drivers'
Monday, July 20, 2015 - 8:33am | 261In a report published Monday, H.C. Wainwright analyst Andrew S. Fein downgraded the rating on Epizyme Inc (NASDAQ: EPZM) to Neutral, while reducing the price target from $45 to $22, citing the absence of any material value drivers in the near- to mid-term. Analyst Andrew Fein mentioned that...